Jung Min Ko

Jung Min Ko

Auto-generated profile, based on publicly available information

Jung Min Ko

Department of Pediatrics, Seoul National University College of Medicine, Seoul National University Children's Hospital, Seoul, Korea.

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2016 in Journal of Korean Neurosurgical Society
Verified
Journal Article
Open access
PDF file
JKJung Min Ko
Jung Min Ko
Ko JM. J Korean Neurosurg Soc. 2016 May;59(3):187-191. http://dx.doi.org/10.3340/jkns.2016.59.3.187

1 January 2015 in Korean Circulation Journal
Verified
Journal Article
Open access
PDF file
JKJung Min Ko
Jung Min Ko
Korean Circulation Journal 대한심장학회지 순환기 Ko JM. Korean Circ J. 2015 Sep;45(5):357-361. https://doi.org/10.4070/kcj.2015.45.5.357

1 January 2015 in Korean Journal of Pediatrics
Verified
Journal Article
Open access
PDF file
CCChong Kun Cheon
Chong Kun Cheon
JKJung Min Ko
Jung Min Ko
Kabuki syndrome (KS) is a rare syndrome characterized by multiple congenital anomalies and mental retardation. Other characteristics include a peculiar facial gestalt, short stature, skeletal and visceral abnormalities, cardiac anomalies, and immunological defects. Whole exome sequencing has uncovered the genetic basis of KS. Prior to 2013, there was no molecular genetic information about KS in Korean patients. More recently, direct Sanger sequencing and exome sequencing revealed KMT2D variants in 11 Korean patients and a KDM6A variant in one Korean patient. The high detection rate of KMT2D and KDM6A mutations (92.3%) is expected owing to the strict criteria used to establish a clinical diagnosis. Increased awareness and understanding of KS among clinicians is important for diagnosis and management of KS and for primary care of KS patients. Because mutation detection rates rely on the accuracy of the clinical diagnosis and the inclusion or exclusion of atypical cases, recognition of KS will facilitate the identification of novel mutations. A brief review of KS is provided, highlighting the clinical and genetic characteristics of patients with KS.

1 June 2013 in Pediatric Neurology
Verified
Journal Article
Closed access
JKJung Min Ko
Jung Min Ko
YSYoung Bae Sohn
Young Bae Sohn
SJSeon Yong Jeong
Seon Yong Jeong
HKHyon-Ju Kim
Hyon-Ju Kim
LMLudwine M. Messiaen
Ludwine M. Messiaen

1 January 2014 in Journal of Korean Medical Science
Verified
Journal Article
Open access
PDF file
YRYoung-Jun Rhie
Young-Jun Rhie
KLKee-Hyoung Lee
Kee-Hyoung Lee
JKJung Min Ko
Jung Min Ko
WLWoo Jung Lee
Woo Jung Lee
JKJung Hyun Kim
Jung Hyun Kim
HKHo-Seong Kim
Ho-Seong Kim
Rhie YJ, et al. J Korean Med Sci. 2014 Aug;29(8):1120-1125. https://doi.org/10.3346/jkms.2014.29.8.1120

10 August 2020 in Orphanet Journal of Rare Diseases
Verified
Journal Article
Open access
PDF file
HPHyun Jin Park
Hyun Jin Park
CSChang Ho Shin
Chang Ho Shin
WYWon Joon Yoo
Won Joon Yoo
TCTae-Joon Cho
Tae-Joon Cho
MKMan Jin Kim
Man Jin Kim
JKJung Min Ko
Jung Min Ko
Background: Megalencephaly-capillary malformation-polymicrogyria syndrome (MCAP) belongs to a group of conditions called the PIK3CA-related overgrowth spectrum (PROS). The varying phenotypes and low frequencies of each somatic mosaic variant make confirmative diagnosis difficult. We present 12 patients who were diagnosed clinically and genetically with MCAP. Genomic DNA was extracted mainly from the skin of affected lesions, also from peripheral blood leukocytes and buccal epithelial cells, and target panel sequencing using high-depth next-generation sequencing technology was performed. Results: Macrocephaly was present in 11/12 patients (92%). All patients had normal body asymmetry. Cutaneous vascular malformation was found in 10/12 patients (83%). Megalencephaly or hemimegalencephaly was noted in all 11 patients who underwent brain magnetic resonance imaging. Arnold–Chiari type I malformation was also seen in 10 patients. Every patient was identified as having pathogenic or likely pathogenic variants of the PIK3CA gene. The variant allele frequency (VAF) ranged from 6.3 to 35.3%, however, there was no direct correlation between VAF and the severity of associated anomalies. c.2740G > A (p.Gly914Arg) was most commonly found, in four patients (33%). No malignancies developed during follow-up periods. Conclusions: This is the first and largest cohort of molecularly diagnosed patients with MCAP in Korea. Targeted therapy with a PI3K-specific inhibitor, alpelisib, has shown successful outcomes in patients with PROS in a pilot clinical study, so early diagnosis for genetic counseling and timely introduction of emerging treatments might be achieved in the future through optimal genetic testing.